People with type 2 diabetes develop Alzheimer’s disease at a rate of roughly 4.7 new cases per 1,000 person-years, and face a 53% higher adjusted relative risk than those without diabetes, a Curtin University-led review of 40 studies published Nov. 9 in Alzheimer’s Research & Therapy found.
The analysis pooled data from more than 27 million participants across the selected studies. Researchers screened 9,431 articles before narrowing to the final set, of which 23 provided incidence data and 26 examined the risk association.
"Relative risk tells us how two groups compare, while incidence tells us how often new cases occur: putting those numbers together gives us a clearer picture of the burden of Alzheimer’s disease among people living with type 2 diabetes," said Emmanuel Adewuyi, an NHMRC Investigator Fellow at the Curtin School of Population Health.
The review focused specifically on type 2 diabetes and Alzheimer’s disease, unlike earlier meta-analyses that often grouped multiple forms of diabetes or dementia together. Adewuyi said the approach offers a more precise understanding of the Alzheimer’s risk among people with type 2 diabetes.
Incidence estimates varied by study methodology. Administrative health-record studies reported an average of 4.00 new Alzheimer’s cases per 1,000 person-years, compared with 10.24 in studies using other diagnostic identification methods. Among people with type 2 diabetes, incidence was numerically higher in women than in men — 3.62 versus 2.76 cases per 1,000 person-years — though the relative risk increase associated with diabetes was similar by sex, at 73% for women and 76% for men.
The authors caution that the findings demonstrate an association, not a direct causal relationship. Additional analyses generally supported the overall results, although incidence estimates varied considerably across studies.
The study appears in Alzheimer’s Research & Therapy, a peer‑reviewed open‑access medical journal established in 2009 and published by BioMed Central with affiliation to Alzheimer’s Research UK. The journal covers basic research, clinical trials, drug discovery and epidemiologic studies in Alzheimer’s disease. Its 2023 Journal Citation Reports impact factor is 8.0, reflecting its standing in the dementia research field.
Study reference: Thi Thu Huong Nguyen et al., "Incidence and risk of Alzheimer’s disease in individuals with type 2 diabetes: a systematic review and meta-analysis," Alzheimer’s Research & Therapy (2026), DOI: 10.1186/s13195-026-02254-7.